Atea Gets FDA Fast-Track Designation for AT-752 in Dengue

By Colin Kellaher

Atea Pharmaceuticals Inc. on Monday said the U.S. Food and Drug Administration granted fast-track designation to AT-752, its oral antiviral candidate for the treatment of dengue virus infection.

The Boston clinical-stage biopharmaceutical company said AT-752 is in Phase 2 clinical development and was generally well tolerated in a Phase 1 study.

The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs.

Atea said there are no currently approved treatments for dengue, a mosquito-borne viral infection that infects up to 400 million people a year.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

09-26-22 0729ET